Drug
Azd7009
Azd7009: highest development phase Phase 2, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| AZD7009, no generic name available NCT00255281 | Phase 2 | Atrial Fibrillation |
Latest
No recent events.
Follow Azd7009 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.